YCG
IDXX icon

Yeomans Consulting Group’s Idexx Laboratories IDXX Stock Holding History

Yeomans Consulting Group’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-725
Closed -$450K – 124
2025
Q3 		$450K Buy
+725
New +$440K 0.16% 66

Other funds holding IDXX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Yeomans Consulting Group's IDXX Position: Q4 2025 in Review

Yeomans Consulting Group sold out of Idexx Laboratories (IDXX) in Q4 2025, closing a stake of 725 shares — an estimated $450K sold.

Yeomans Consulting Group first reported a position in IDXX in Q3 2025 and held it in 1 quarter. The position peaked at $450K in Q3 2025. 1,386 funds tracked by Wall St. Rank hold IDXX as of Q4 2025.

  • Yeomans Consulting Group reported no remaining Idexx Laboratories position as of Q4 2025 after selling out during the quarter.
  • Yeomans Consulting Group sold 725 Idexx Laboratories shares in Q4 2025, an estimated $450K.
  • Yeomans Consulting Group first reported a position in Idexx Laboratories in Q3 2025 and held it in 1 quarter.
  • Yeomans Consulting Group's Idexx Laboratories position peaked at $450K in Q3 2025.
  • 1,386 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2025.

Based on Yeomans Consulting Group's 13F filing for Q4 2025, filed 7 Jan 2026.